How to treat asthma in 2021? Goodbye SABA, hello MART and welcome triple therapy

A. Papi (Ferrara, Italy)

Source: Virtual Congress 2021 – Airway diseases
Session: Airway diseases
Session type: State of the art session
Number: 114

WebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Papi (Ferrara, Italy). How to treat asthma in 2021? Goodbye SABA, hello MART and welcome triple therapy. Virtual Congress 2021 – Airway diseases

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Optimising bronchodilator therapy in COPD: Who, why and when?
Source: International Congress 2019 – Personalised medicine in COPD: Matching the patient needs with the right care
Year: 2019

Can " Beta-blockers" be useful to treat asthma?
Source: Annual Congress 2009 - Beta-blockers may now be beneficial in asthma and COPD
Year: 2009

Long-acting bronchodilators in COPD: where are we now and where are we going?
Source: Breathe 2014; 10:110-120
Year: 2014

How often do asthma patients claim prescribed therapy?
Source: International Congress 2017 – Asthma from childhood to adulthood and ACOS
Year: 2017

Inhaled therapies: can they breathe new life into asthma?
Source: International Congress 2019 – The journey towards personalized medicine in asthma: where are we now?
Year: 2019

Inhaled corticosteroids in COPD: friend or foe?
Source: Eur Respir J, 52 (6) 1801219; 10.1183/13993003.01219-2018
Year: 2018

Late Breaking Abstract - Overprescription of short-acting beta2-agonists in asthma management? Pharmacy reports from 91,673 patients in Poland
Source: International Congress 2019 – New towards old therapies in airway diseases
Year: 2019

Making simple things complicated using anti-inflammatory reliever therapy
Source: Eur Respir J, 55 (4) 2000267; 10.1183/13993003.00267-2020
Year: 2020

The sustainability agenda and inhaled therapy: what do patients want?
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021

LAMA/LABA vs. LABA/ICS and triple therapy – is ICS in again?
Source: International Congress 2018 – Preventing asthma and COPD exacerbations by increasing the inhaled glucocorticoid dose
Year: 2018

Budesonide/formoterol maintenance and reliever therapy for asthma in general practice: is it cost-effective?
Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care
Year: 2008

CPAP holiday: are we there yet?
Source: Eur Respir J 2015; 45: 574-575
Year: 2015

Spacer devices for inhaled therapy: why use them, and how?
Source: ERJ Open Res, 4 (2) 00065-2018; 10.1183/23120541.00065-2018
Year: 2018

CPAP holiday: are we there yet?
Source: Eur Respir J 2015; 45: 575-576
Year: 2015

Late Breaking Abstract - Impact of maintenance and reliever therapy (MART)-focused asthma guideline on SABA prescriptions
Source: Virtual Congress 2021 – Highlights for primary care in 2021
Year: 2021

“My reliever helps me control my asthma”: patient attitudes to asthma inhalers
Source: International Congress 2018 – The complexities of managing mild asthma
Year: 2018

What to use INSTEAD of inhaled corticosteroids in COPD?
Source: Eur Respir J 2014; 44: 1391-1393
Year: 2014

Treating non-adherence: the rest is pointless if the drugs stay in the cupboard!
Source: International Congress 2017 – Cystic fibrosis in children and adults: treatment dilemmas
Year: 2017

Why isn't his asthma getting better Doctor?
Source: ERS Live 2009
Year: 2009